ABT‐199, a specific Bcl‐2 inhibitor, showed promising therapeutic efficacy in early phase clinical trials in Bcl‐2‐dependent tumor including MM patients with a t(11;14) translocation.56 However, ABT‐199 had very limited activity in myeloma patients who did not have the t(11;14) translocation, which accounts for >75% of myeloma patients. The gene discussed is BCL2; the disease is plasma cell myeloma.